跳至主要内容
临床试验/NCT05678296
NCT05678296已完成不适用

Investigation of Effectiveness of Local Antibiotic Applications With Platelet Rich Fibrin on Third Molar Surgery Outcomes In Vivo and In Vitro

Ceren Melahat Donmezer1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年4月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
visual analogue scale (VAS)

研究概览

简要总结

The aim of this study was investigate the effectiveness of Local Antibiotic Applications With Platelet Rich Fibrin on Third Molar Surgery Outcomes In Vivo and In Vitro. The study included a total of 60 patients with impacted mandibular third molar. Patients were evaluated in 3 randomly separated groups. For the first and second group, Platelets Rich Fibrin+ local antibiotics were applied into the tooth socket. For the first group, amoxicillin was applied and for the second group, clindamycin was applied. There was a control group which only Platelets Rich Fibrin was applied into the socket. The outcome variables were pain, swelling, the number of analgesics taken, and trismus. These variables were also assessed based on first, second, third, and seventh days following the operation.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • patient with no systemic diseases, no current infection, no smoke, no pregnancy

排除标准

  • no inflammation

研究组 & 干预措施

control group

platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.

干预措施: Diagnosis (Diagnostic Test)

control group

platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.

干预措施: Analgesic (Drug)

control group

platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.

干预措施: traditional osteotomies (Procedure)

control group

platelet-rich fibrin placed into the socket of extracted tooth and no antibiotic is prescribed.

干预措施: Platelet Rich Fibrin (Biological)

group 1

platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.

干预措施: Diagnosis (Diagnostic Test)

group 1

platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.

干预措施: Analgesic (Drug)

group 1

platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.

干预措施: traditional osteotomies (Procedure)

group 1

platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.

干预措施: Platelet Rich Fibrin (Biological)

group 1

platelet-rich fibrin + 0.5 ml amoklavin I.V. 1.2 gr placed into the socket of the extracted tooth.

干预措施: Antibiotic (Drug)

group 2

platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.

干预措施: Diagnosis (Diagnostic Test)

group 2

platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.

干预措施: Analgesic (Drug)

group 2

platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.

干预措施: traditional osteotomies (Procedure)

group 2

platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.

干预措施: Platelet Rich Fibrin (Biological)

group 2

platelet-rich fibrin + 0.5 ml Clin 600 mg/4 ml IM/IV, 0.5 ml placed into the socket of the extracted tooth.

干预措施: Antibiotic (Drug)

结局指标

主要结局

visual analogue scale (VAS)

时间窗: Day 15

It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured.

swelling

时间窗: Day 15

measured using a flexible plastic measuring tape as described by Gabka and Matsumura by measuring the distance from the corner of the mouth to the attachment of the earlobe following the bulge of the cheek and the distance from the outer canthus of the eye to the angle of the mandible.

Trismus

时间窗: Day 15

Trismus by measuring the distance between the mesial incisal corners of the upper and lower right incisors during maximum mouth opening.

次要结局

未报告次要终点

研究者

发起方
Ceren Melahat Donmezer
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Ceren Melahat Donmezer

Principal Investigator, Oral and Maxillofacial Surgeon

Near East University, Turkey

研究点 (1)

Loading locations...

相似试验